17,034 Shares in Edwards Lifesciences Corporation $EW Bought by USA Financial Formulas

Key Points

• USA Financial Formulas has acquired 17,034 shares of Edwards Lifesciences Corporation for approximately $1.3 million, marking a new position for the firm as of the second quarter.
• Significant growth in institutional investment was seen as multiple firms, including Nuveen LLC and AQR Capital Management, increased their stakes in Edwards Lifesciences during the first quarter.
• Analysts have raised their price targets for Edwards Lifesciences, with the consensus target now at $86.61, reflecting strong investor sentiment toward the company.

USA Financial Formulas bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 17,034 shares of the medical research company's stock, valued at approximately $1,332,000.

Several other institutional investors have also recently bought and sold shares of EW. Nuveen LLC acquired a new stake in Edwards Lifesciences in the 1st quarter worth $330,881,000. Jennison Associates LLC grew its position in Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. Woodline Partners LP grew its position in Edwards Lifesciences by 7,805.0% in the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company's stock worth $59,822,000 after purchasing an additional 814,917 shares during the last quarter. AQR Capital Management LLC grew its position in Edwards Lifesciences by 339.7% in the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company's stock worth $65,381,000 after purchasing an additional 709,648 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in Edwards Lifesciences by 37.0% in the 1st quarter. BNP Paribas Financial Markets now owns 1,946,818 shares of the medical research company's stock worth $141,105,000 after purchasing an additional 525,822 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Finally, Stifel Nicolaus set a $85.00 target price on shares of Edwards Lifesciences and gave the company a "buy" rating in a research report on Monday, September 22nd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $86.61.

Edwards Lifesciences Price Performance

NYSE:EW opened at $76.42 on Thursday. The firm has a market cap of $44.86 billion, a PE ratio of 10.99, a price-to-earnings-growth ratio of 3.74 and a beta of 1.05. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company's 50-day moving average price is $78.53 and its two-hundred day moving average price is $75.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the business earned $0.70 earnings per share. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.